Solubility of lumiracoxib in supercritical carbon dioxide

• Published in: Scientific reports 2024-06, Vol.14 (1), p.13260-16
• Main Authors: Albadran, Firas H., Abbood, Nabeel K., Al-Mayyahi, Mohammad A., Hosseini, Seyednooroldin, Abed, Mohammed S.
• Format: Article
• Language: English
• Subjects: 639/166; 639/301; 639/638; Anti-inflammatory agents; Carbon dioxide; Crossover pressure; Drug dosages; Humanities and Social Sciences; Lumiracoxib; multidisciplinary; Nimesulide; Nonsteroidal anti-inflammatory drugs; Osteoarthritis; Particle size; Rheumatoid arthritis; Science; Science (multidisciplinary); Solubility; Solvents; Supercritical carbon dioxide; Temperature
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-024-63416-x

This study aims to use a static-based solubility method for measuring the solubility of lumiracoxib at a temperature of 308–338 K and pressure of 120–400 bar for the first time. The obtained solubility data for lumiracoxib is between 4.74 × 10 −5 and 3.46 × 10 −4 (mole fraction) for the studied ranges of pressure and temperature. The solubility values reveal that the lumiracoxib experiences a crossover pressure of about 160 bar. Moreover, the measured solubility data of these two drugs are correlated with density-based semi-empirical correlations namely Bartle et al., Mendez-Santiago-Teja, Kumar and Johnstone, Chrastil and modified Chrastil models with an average absolute relative deviation of 10.7%, 9.5%, 9.8%, 7.8%, and 8.7% respectively for lumiracoxib. According to these findings, it is obvious that all of the examined models are rather accurate and there is no superiority between these models for both examined drugs although the Chrastil model is slightly better in the overall view.